Background:Icrucumab IMC-18F1, a human monoclonal antibody against vascular endothelial growth factor receptor-1 VEGFR-1, potently inhibits ligand-dependent phosphorylation of VEGFR-1 and downstream signaling, making icrucumab an attractive candidate for antitumor activity.